A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza białaczki limfocytowej przewlekłej lub chłoniaka limfocytowego
- •Choroba, która nawróciła po co najmniej jednym wcześniejszym leczeniu lub nie reaguje na leczenie
- •Zdolność do połykania i przyjmowania leków doustnych
- •Ogólny stan zdrowia oceniony jako 0-2 w skali ECOG (możliwość codziennych aktywności)
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Prawidłowe funkcjonowanie nerek, wątroby i innych narządów
- •Jeśli dotyczy: leczenie wirusem zapalenia wątroby B lub C lub HIV musi być stabilne
- •Zdolność do stosowania skutecznej antykoncepcji (dla osób mogących mieć dzieci)
✗ Disqualifies
- •Aktywna infekcja wirusem zapalenia wątroby B lub C
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (55)
Highlands Oncology Group ( Site 5405)
Springdale, United States
MemorialCare Health System - Long Beach Medical Center ( Site 5421)
Long Beach, United States
Memorial Hospital West ( Site 5410)
Pembroke Pines, United States
Oregon Health and Science University ( Site 5425)
Portland, United States
Medical Oncology Associates, PS ( Site 5406)
Spokane, United States
University of Wisconsin Hospital and Clinics-Carbone Cancer Center ( Site 5423)
Madison, United States
Instituto Alexander Fleming ( Site 1005)
Ciudad Autónoma de Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 1007)
Mar del Plata, Argentina
Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Hematology ( Site 1002)
Buenos Aires, Argentina
Sanatorio Parque ( Site 1003)
Rosario, Argentina
Centro Medico Fleischer ( Site 1006)
Buenos Aires, Argentina
Hospital Aleman-oncohematologic diseases ( Site 1001)
Buenos Aires, Argentina
Royal Adelaide Hospital ( Site 1104)
Adelaide, Australia
Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 1103)
Melbourne, Australia
UZ Leuven-Hematology ( Site 1200)
Leuven, Belgium
ZAS Cadix ( Site 1203)
Antwerp, Belgium
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308)
São Paulo, Brazil
The Moncton Hospital ( Site 1414)
Moncton, Canada
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 1402)
Greenfield Park, Canada
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 1410)
Sherbrooke, Canada
Biocenter ( Site 1507)
Concepción, Chile
IC La Serena Research ( Site 1506)
La Serena, Chile
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1509)
Santiago, Chile
FALP-UIDO ( Site 1500)
Santiago, Chile
Clínica Inmunocel ( Site 1511)
Santiago, Chile
Fundación Valle del Lili ( Site 1703)
Cali, Colombia
Hopital Claude Huriez - CHU de Lille ( Site 2107)
Lille, France
Centre Hospitalier Universitaire Estaing ( Site 2105)
Clermont-Ferrand, France
CHD Vendee ( Site 2100)
La Roche-sur-Yon, France
Klinikum Mutterhaus der Borromäerinnen-Innere Medizin I ( Site 2203)
Trier, Germany
Universitätsklinikum Leipzig-Medical Department I - Hematology and Celltherapy ( Site 2201)
Leipzig, Germany
Rambam Health Care Campus ( Site 2801)
Haifa, Israel
Hadassah Medical Center-Hemato-Oncology ( Site 2812)
Jerusalem, Israel
Sheba Medical Center-Hemato Oncology ( Site 2809)
Ramat Gan, Israel
Sourasky Medical Center ( Site 2811)
Tel Aviv, Israel
Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2906)
Alessandria, Italy
Ospedale San Raffaele-Programma di Ricerca Strategica sulla LLC ( Site 2902)
Milan, Italy
Arcispedale Santa Maria Nuova-Hematology ( Site 2900)
Reggio Emilia, Italy
Centro de Infusion Superare ( Site 3314)
Mexico City, Mexico
Health Pharma Professional Research S.A. de C.V: ( Site 3301)
Mexico City, Mexico
Centro de Investigacion Clinica Chapultepec ( Site 3309)
Morelia, Mexico
Auxilio Mutuo Cancer Center ( Site 3900)
San Juan, Puerto Rico
Alberts Cellular Therapy. ( Site 4401)
Pretoria, South Africa
Groote Schuur Hospital ( Site 4400)
Cape Town, South Africa
Haemalife ( Site 4407)
Kuilsriver, South Africa
Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4601)
L'Hospitalet Del Llobregat, Spain
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 4602)
Pozuelo de Alarcón, Spain
HOSPITAL CLINICO DE VALENCIA-HEMATOLOGY ( Site 4603)
Valencia, Spain
Ege Universitesi Hastanesi ( Site 4902)
Bornova, Turkey (Türkiye)
Namik Kemal University Medical Faculty-Hematology ( Site 4912)
Tekirdağ, Turkey (Türkiye)
Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 4913)
Ankara, Turkey (Türkiye)
Mega Medipol-Hematology ( Site 4904)
Istanbul, Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 4906)
Istanbul, Turkey (Türkiye)
City Hospital, Nottingham University Hospitals-Hematology ( Site 5002)
Nottingham, United Kingdom
University College London Hospital-Cancer Clinical Trials Unit ( Site 5001)
London-Camden, United Kingdom
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.